The study is a single arm, nonrandomized phase II prospective study, with the goal of investigating the role of screening brain MRIs in neurologically asymptomatic patients with metastatic breast cancer.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SCREENING
Masking
NONE
Enrollment
170
Participants will undergo MRI imaging with and without contrast.
Morton Plant Mease- Baycare
Clearwater, Florida, United States
RECRUITINGMoffitt Cancer Center
Tampa, Florida, United States
ACTIVE_NOT_RECRUITINGRate of Brain Metastasis
Rate of brain metastasis by breast cancer subtype at baseline using MRI images.
Time frame: at Baseline
Rate of Brain Metastasis
Rate of brain metastasis by breast cancer subtype at 6 months or first systemic progression using MRI images.
Time frame: up to 6 months
Rate of Asymptomatic Leptomeningeal Disease
Rate of asymptomatic leptomeningeal disease by breast cancer subtype at baseline and at 6 months or first systemic progression, using MRI images.
Time frame: Baseline and at up to 6 months
Number of Brain Metastases
Number of Brain Metastases at Diagnosis by Breast Cancer Subtype, using MRI images.
Time frame: Baseline
Overall Survival
Overall Survival (OS) will be measured from the initial on study date to the recorded date of death.
Time frame: Up to 6 months
Number of Participants Requiring Whole Brain Radiation Therapy vs Stereotactic Radiation
Number of Participants Requiring Whole Brain Radiation Therapy vs Stereotactic Radiation by breast cancer type.
Time frame: Up to 6 months
Brain Metastasis Specific Survival
Brain metastasis specific survival following brain metastasis by breast cancer subtype
Time frame: Up to 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.